James J. Mulay - 09 Oct 2025 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Role
Director
Signature
/s/ Joshua F. Patterson, Attorney-in-Fact for James J. Mulay
Issuer symbol
CGON
Transactions as of
09 Oct 2025
Net transactions value
-$237,714
Form type
4
Filing time
10 Oct 2025, 16:15:03 UTC
Previous filing
30 Sep 2025
Next filing
13 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mulay James Director C/O CG ONCOLOGY, INC., 400 SPECTRUM CENTER DRIVE, SUITE 2040, IRVINE /s/ Joshua F. Patterson, Attorney-in-Fact for James J. Mulay 10 Oct 2025 0001684531

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGON Common Stock Options Exercise $21,959 +5,903 $3.72 5,903 09 Oct 2025 Direct
transaction CGON Common Stock Sale $259,673 -5,903 -100% $43.99 0 09 Oct 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGON Director Stock Option (right to buy) Options Exercise $0 -5,903 -75% $0.000000 1,962 09 Oct 2025 Common Stock 5,903 $3.72 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
F2 The stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023.